YEDA RESEARCH AND DEVELOPMENT CO. LTD. Patent applications |
Patent application number | Title | Published |
20160122775 | PLANT WITH ALTERED CONTENT OF STEROIDAL GLYCOALKALOIDS - The present invention relates to genetically modified plants by key genes involved in the biosynthesis of steroidal alkaloids. These plants have altered content of steroidal (glyco)alkaloids. Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids are provided. | 05-05-2016 |
20160122391 | SHORT BETA-DEFENSIN-DERIVED PEPTIDES - The invention is directed to β-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer. | 05-05-2016 |
20160069896 | DIAGNOSIS OF AUTOIMMUNE DISEASES USING A SPECIFIC ANTIBODY PROFILE - Methods and kits for diagnosing systemic lupus erythematosus (SLE) or scleroderma in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing SLE or scleroderma in a subject. | 03-10-2016 |
20160033529 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME - The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers. | 02-04-2016 |
20160000821 | MICRO-RNAS AND COMPOSITIONS COMPRISING SAME FOR THE TREATMENT AND DIAGNOSIS OF SEROTONIN-, ADRENALIN-, NORADRENALIN-, GLUTAMATE-, AND CORTICOTROPIN-RELEASING HORMONE- ASSOCIATED MEDICAL CONDITIONS - microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided. | 01-07-2016 |
20150344972 | COMPOSITIONS COMPRISING SOLUBLE CD84 OR ANTI-CD84 ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING B-CLL - A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL. | 12-03-2015 |
20150297693 | PEPTIDE INHIBITORS FOR MEDIATING STRESS RESPONSES - The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides. | 10-22-2015 |
20150216949 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM - A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer of the central nervous system in the subject. | 08-06-2015 |
20150202310 | ALBUMIN BINDING PROBES AND DRUG CONJUGATES THEREOF - The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof. | 07-23-2015 |
20150190546 | THERAPEUTIC TRANSPLANTATION USING DEVELOPING, HUMAN OR PORCINE, RENAL OR HEPATIC, GRAFTS - A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage. | 07-09-2015 |
20150175671 | OIL GLOBULE PROTEIN AND USES THEREOF - An isolated novel oil globule protein encoded by a polynucleotide sequence is provided together with a composition which includes the isolated protein. A transgenic organism transformed by a polynucleotide encoding a protein which at least partially comprises the amino acid sequence of the novel oil globule protein is also provided. The invention also provides a method for producing or enhancing the production of a carotenoid such as astaxanthin, which is an oil globule constituent. | 06-25-2015 |
20150174294 | DISEASE TREATMENT VIA DEVELOPING NON-SYNGENEIC GRAFT TRANSPLANTATION - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 06-25-2015 |
20150158953 | REGULATORS OF MMP-9 AND USES THEREOF - A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9. Molecules capable of specifically interacting with the OG domain, methods of identifying same, pharmaceutical compositions comprising same and uses thereof are also disclosed. | 06-11-2015 |
20150144498 | DEVICE AND APPARATUS FOR CARRYING OUT CHEMICAL DISSOCIATION REACTIONS AT ELEVATED TEMPERATURES - A reactor is provided which comprises: a plurality of reaction units located within a reaction zone, each of the reaction units being adapted to enable carrying out a chemical reaction of one or more raw gases (e.g. at least one of CO2 and H20); ingress means to allow introduction of the one or more raw gases into the reaction zone and to allow distributing the incoming gas to the plurality of reaction units; egress means to allow exit of reaction products from the reaction zone; and a heating system. The reaction units extend essentially along a longitudinal axis of the reaction zone and are arranged in a spaced-apart relationship along a lateral axis of the reaction zone. The heating system comprises a plurality of heating sources extending along the reaction zone, thereby providing at least a part of the energy to carry out the reaction process within the reaction units. | 05-28-2015 |
20150125433 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS - A method of increasing insulin content in a pancreatic beta cell is disclosed. The method comprising expressing in the pancreatic beta cell an exogenous polynucleotide encoding at least one microRNA or a precursor thereof, wherein the microRNA is selected from the group consisting of miR-15, miR-16, miR-24, miR-26, miR-27, miR-29, miR-30, miR-129, miR-141, miR-148, miR-182, miR-200, miR-376 and Let-7, thereby increasing the insulin content in the pancreatic beta cell. | 05-07-2015 |
20150104471 | UNIVERSAL DONOR-DERIVED TOLEROGENIC CELLS FOR INDUCING NON-SYNGENEIC TRANSPLANTATION TOLERANCE - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject | 04-16-2015 |
20150051151 | Modified Kisspeptin Peptides and Uses Thereof - The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease. | 02-19-2015 |
20150049542 | MEMORY AND LOGIC DEVICE AND METHODS FOR PERFORMING THEREOF - In accordance with one exemplary embodiment of the present technique, there is disclosed a spins selective device, including a first layer comprising a ferromagnetic material. The spin selective device further includes a second layer coupled to the first layer. The second layer includes at least one molecule having a specified chirality, such that when an electrical current flows between the first layer and the second layer one or more regions of the ferromagnetic material become magnetically polarized along a certain direction. | 02-19-2015 |
20150030560 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS - The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal. | 01-29-2015 |
20150010512 | Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 01-08-2015 |
20140378888 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS - An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies such as corneal thinning and scleral stretching. | 12-25-2014 |
20140322179 | METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS - A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. | 10-30-2014 |
20140315301 | ISOLATED NAIVE PLURIPOTENT STEM CELLS AND METHODS OF GENERATING SAME - Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor. | 10-23-2014 |
20140303479 | MAGNETIC RESONANCE IMAGING FOR DETECTING CARDIAC DISEASES - The invention provides magnetic resonance imaging methods for detecting cardiac diseases including myocardial fibrosis. Specifically, the invention provides a magnetic resonance imaging (MRI) pulse sequence that could be used to perform magnetization transfer (MT) or chemical exchange saturation transfer (CEST) in the heart. | 10-09-2014 |
20140287264 | ORDERED STACKED SHEETS OF LAYERED INORGANIC COMPOUNDS, NANOSTRUCTURES COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF - Provided is a nanostructure including ordered stacked sheets and processes for its preparation and use. | 09-25-2014 |
20140248293 | NOVEL RISK BIOMARKERS FOR LUNG CANCER - Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer. | 09-04-2014 |
20140243393 | METHODS OF DIAGNOSING AND TREATING MOTOR NEURON DISEASES - Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND). | 08-28-2014 |
20140237686 | Transgenic Plants Resistant To Non-Protein Amino Acids - Transgenic plants resistant to bio-herbicides, particularly to phytotoxic non-protein amino acids including the meta-tyrosine (m-tyrosine) amino acid analog and salts thereof, means and methods for producing the transgenic plants. | 08-21-2014 |
20140221269 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME - An odorant mixture is disclosed. The odorant mixture comprises N odorant components wherein N equals at least 20. Each odorant component is characterized by a multidimensional vector of attributes. A z score of an average of characteristic distances between vectors corresponding to odorant components in the mixture and vectors corresponding to odorant components in a group of M odorant components but not in the mixture is less than 2. | 08-07-2014 |
20140220074 | Toll-Like Receptor 4 (Tlr-4) Agonist Peptides For Modulating Tlr-4 Mediated Immune Response - Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer. | 08-07-2014 |
20140219979 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders. | 08-07-2014 |
20140212438 | NUCLEAR TARGETING SEQUENCES - Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed. | 07-31-2014 |
20140212398 | ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT - A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype. | 07-31-2014 |
20140212395 | DOWNREGULATION OF miR-7 FOR PROMOTION OF BETA CELL DIFFERENTIATION AND INSULIN PRODUCTION - A method of ex-vivo increasing insulin content in beta cells or stem cells is disclosed. The method comprising contacting the beta cells or stem cells with an agent for downregulating an activity or expression of miR-7, thereby increasing the insulin content in the beta cells or stem cells. | 07-31-2014 |
20140207433 | SYSTEMS AND METHODS OF MONITORING SOCIAL INTERACTIONS IN A GROUP OF ORGANISMS OVER A PERIOD OF AT LEAST 24 HOURS IN A SEMI-NATURAL ENVIRONMENT - A method of monitoring social interactions among a plurality of model organisms. The method comprises marking each of a plurality of model organisms in a monitored space, divided to a plurality of spatial segments, with one of a plurality of unique visual markers, capturing a sequence of images of the plurality of unique visual markers, calculating at least one spatiotemporal model of at least one of the plurality of model organisms by identifying in which of the plurality of segments each unique visual marker is located during each of a plurality of temporal frames of a period, and outputting the at least one spatiotemporal model. | 07-24-2014 |
20140200159 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 07-17-2014 |
20140199675 | SOCIAL NETWORK BASED EDUCATION INFRASTRUCTURE AND METHODS OF IMPLEMENTING AND USING SOCIAL NETWORK BASED EDUCATION INFRASTRUCTURES - A method for enabling users to offer educational support in response to a designation of instructor identifier (ID) tags associated with network accessible learning documents. The method comprises selecting by a first user using a first client terminal a network accessible learning document, associating an instructor ID tag indicative of the first user with the network accessible learning document, instructing a presentation of the instructor ID tag in association with the presentation of the network accessible learning document to a second user accessing the network accessible learning document via a second client terminal, identifying a user selection designating the instructor ID tag and made by the second user, and establishing a tutorial session which is based on an interactive communication connection between the first user and the second user. | 07-17-2014 |
20140194593 | COPOLYMER 1 RELATED POLYPEPTIDES FOR USE AS MOLECULAR WEIGHT MARKERS AND FOR THERAPEUTIC USE - The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer. | 07-10-2014 |
20140179934 | OLIGO- AND POLYFURANS, PREPARATION AND USES THEREOF - This invention is directed to oligofurans, process of preparation and uses thereof. | 06-26-2014 |
20140178899 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER AND NEURODEGENERATIVE DISEASES RELATED TO BECLIN-1 - The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases. | 06-26-2014 |
20140178353 | BACTERIAL ANTI-PHAGE DEFENSE SYSTEMS - An isolated polypeptide is disclosed comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2773-5544 and 11089-11094, wherein the polypeptide has antimicrobial activity. Uses thereof for treating microbial infections are also disclosed. | 06-26-2014 |
20140170675 | PROTEIN DETECTOR BASED ON MOLECULAR CONTROLLED SEMICONDUCTOR RESISTOR - The invention provides a semiconductor device for the detection of an active site-containing protein or a ligand thereof in a solution, said device comprising at least one insulating or semi-insulating layer; at least one conducting semiconductor layer, two conducting pads on top of the upper layer making electrical contact with said at least one conducting semi-conductor layer, such that electrical current can flow between them at a finite distance from the surface of the device; a protective molecular layer fabricated on top of said upper layer and protecting said layer from corrosion; and said ligand or active site-containing protein linked to said protective molecular layer. Exposure of said ligand or active site-containing protein to a solution containing said active site-containing protein or ligand, respectively, causes a current change through the device when a constant electric potential is applied between the two conducting pads. The semi-conductor device can be seen as a molecularly controlled semiconductor resistor (MOCSER) protein sensor based on doped and undoped GaAs stack structure. The GaAs is protected against etching in aqueous environments by the protective molecular layer. | 06-19-2014 |
20140167958 | METHOD FOR AUTOMATIC BEHAVIORAL PHENOTYPING - A method of identifying and classifying social complex behaviors among a group of model organisms, comprising implanting at least one RFID transponder in each model organism in said group of model organisms; enclosing said group of model organisms in a monitored space divided into RFID monitored segments; RFID tracking a position of each model organism by reading said at least one RFID transponder in each model organism over a period of time; capturing a sequence of images of each model organism over said period of time; and calculating at least one spatiotemporal model of each model organism based on time synchronization of said RFID tracked position of said model organism with said sequence of images. | 06-19-2014 |
20140155330 | Compositions And Methods For Modulating Apoptosis - Peptides, compositions and methods for modulating apoptosis, useful for treating diseases or disorders characterized by dysregulated apoptosis, such as cancer or neurodegenerative diseases. Screening methods for identifying agents that mediate apoptosis by regulating Atg12 binding to Bcl-2 family members. | 06-05-2014 |
20140154158 | APPARATUS AND METHOD FOR REMOVING SULFER DIOXIDE FROM FLUE GASES - An apparatus and method for removing sulfur dioxide from a flue gas is described. The apparatus has sequentially operable scrubbing zone and regeneration zone, which communicate with one another via a molten eutectic mixture of lithium, sodium and potassium carbonates. In the scrubbing zone, an ingress flue gas interacts with the molten carbonates, resulting in chemical absorbance of the sulfur dioxide and in discharge of reaction gases. In the regeneration zone, ether a chemical or electrochemical melt regeneration takes place resulting in formation of sulfur-containing vapor which is cooled down for converting the sulfur-containing vapor into a liquid and solid phase for a further collection and utilization. | 06-05-2014 |
20140147451 | COMPOSITIONS COMPRISING SOLUBLE CD84 OR ANTI-CD84 ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING B-CLL - A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL. | 05-29-2014 |
20140141014 | ANTIBODIES THAT INHIBIT METALLOPROTEINS - An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed. | 05-22-2014 |
20140134196 | VACCINE AND METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii). | 05-15-2014 |
20140121352 | REVERSIBLE PEGYLATED DRUGS - Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety. | 05-01-2014 |
20140120126 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 05-01-2014 |
20140088293 | PHOTOSYNTHETIC ORGANISMS AND COMPOSITIONS AND METHODS OF GENERATING SAME - An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance. | 03-27-2014 |
20140088017 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME - The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers. | 03-27-2014 |
20140086917 | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER - An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging:
| 03-27-2014 |
20140079682 | PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND COMPOSITIONS AND METHODS UTILIZING SAME - Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes. | 03-20-2014 |
20140066490 | SYSTEM AND METHOD FOR MODIFYING DEOXYRIBOZYMES - A system and method for programming DNAzymes to be utilized as programmable drugs, which are active only in the presence of specific input combinations and/or certain conditions. | 03-06-2014 |
20140066489 | DECREASING OR PREVENTING SUB-SURFACE GEOLOGICAL MATTER CONTAMINATION BY AGROCHEMICALS - Method of exposing agricultural substrates (plant matter | 03-06-2014 |
20140046065 | PROCESS FOR PREPARING AMINES FROM ALCOHOLS AND AMMONIA - The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands. | 02-13-2014 |
20130344041 | GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS - An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed. | 12-26-2013 |
20130338528 | METHOD AND DEVICE FOR MONITORING BREASTFEEDING - A method of monitoring amount of milk consumed by an infant being breastfed by a breast is disclosed. The method comprises: determining variations in electric capacitance of the breast during breastfeeding, and correlating the electric capacitance variations to an amount of milk consumed by the infant. | 12-19-2013 |
20130316358 | METHODS OF DIAGNOSING DISEASE USING OVERLAP EXTENSION PCR - A method of diagnosing a disease in a subject in need thereof is disclosed. The method comprises:
| 11-28-2013 |
20130315881 | METHOD AND ASSAY FOR GLYCOSYLATION PATTERN DETECTION RELATED TO CELL STATE OF STEM CELLS - A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation. | 11-28-2013 |
20130303441 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS - Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are substrate-competitive inhibitors and have an amino acid sequence designed so as to bind to a defined binding site subunit in GSK-3. | 11-14-2013 |
20130266582 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for regulating ROC-mediated death-associated protein kinase (DAPk) activity. The compositions and methods of the present invention are useful for treating or ameliorating cancer as well as pathologies associated with neuronal cell death, such as epilepsy and hypoxia/ischemia acute brain injury. The present invention further relates to screening methods for identifying agents that regulate ROC-mediated DAPk activation. | 10-10-2013 |
20130260386 | NUCLEIC ACID CONSTRUCT SYSTEMS CAPABLE OF DIAGNOSING OR TREATING A CELL STATE - Nucleic acid construct systems are disclosed capable of diagnosing and treating a cell state (e.g. disease state). Methods of diagnosing and treating disease states using the nucleic acid constructs described herein are also disclosed. In addition, methods of screening for agents capable of reversing a disease phenotype using the nucleic acid constructs of the present invention are disclosed. | 10-03-2013 |
20130229018 | ENERGY GENERATION SYSTEM AND METHOD THEREOF - An energy generation system and method are presented for use in operating a heat engine. The energy generation method comprises: reducing a CO | 09-05-2013 |
20130225547 | PROTEASOME INHIBITORS AND USES THEREOF - A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors. | 08-29-2013 |
20130225478 | PEPTIDES BASED ON THE TRANSMEMBRANE DOMAIN OF A TOLL-LIKE RECEPTOR (TLR) FOR TREATMENT OF TLR-MEDIATED DISEASES - Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease. | 08-29-2013 |
20130224225 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12. | 08-29-2013 |
20130209491 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES - A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with:
| 08-15-2013 |
20130209440 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS - A method of increasing insulin content in a pancreatic beta cell is disclosed. The method comprising expressing in the pancreatic beta cell an exogenous polynucleotide encoding at least one microRNA or a precursor thereof, wherein the microRNA is selected from the group consisting of miR-15, miR-16, miR-24, miR-26, miR-27, miR-29, miR-30, miR-129, miR-141, miR-148, miR-182, miR-200, miR-376 and Let-7, thereby increasing the insulin content in the pancreatic beta cell. | 08-15-2013 |
20130206646 | REMOVAL OF HETEROAROMATIC SULFIDES FROM HYDROCARBONS USING POLYOXOMETALATES CATALYSTS - The present invention relates to methods of removing heteroaromatic sulfides from hydrocarbons (e.g. petroleum products such as gasoline and fuel oils), using polyoxometalate catalysts such as H | 08-15-2013 |
20130198900 | "THIAMINE PYROPHOSPHATE (TPP) RIBOSWITCH MUTANTS PRODUCING VITAMIN B1 ENRICHED FOOD AND FEED CROPS" - The present invention provides bioengineered organisms producing elevated levels of thiamine and/or thiamine derivatives. Particularly, the present invention discloses that modifying TPP-responsive riboswitch results in accumulation of thiamine and/or its derivatives. | 08-01-2013 |
20130196874 | SENSOR FOR DETECTION AND IDENTIFICATION OF ANALYTES AND A METHOD THEREOF - The present invention discloses a method and sensor for detection and identification of analytes such as foreign material or DNA and RNA in particular in low concentration. The sensitivity of the method allows the detection of few molecules (down to a single one) independent on the concentration of the sample. There is provided a sensor for analyte(s) detection in a fluid sample. The sensor comprises at least one tube-like member carrying an arrangement of probes patterned thereinside. | 08-01-2013 |
20130183322 | IMMUNOSUPPRESSIVE DRUG COMBINATION FOR A STABLE AND LONG TERM ENGRAFTMENT - A method of treating a subject in need of a cell or tissue transplant is disclosed. The method comprising (a) transplanting a non-syngeneic cell or tissue transplant into the subject, wherein the transplant comprises bone marrow or lymphoid cells; and (b) administering to the subject a therapeutically effective amount of an immunosuppressive regimen comprising a Sphingosine 1-Phosphate Receptor Agonist, a B7 molecule inhibitor and a CD2/CD58 pathway inhibitor, thereby treating the subject. | 07-18-2013 |
20130177871 | ENDODONTIC FILES AND METHOD OF PREPARATION THEREOF - The present invention provides a selective coating of an endodontic file, in which the distal end of the file is uncoated or alternatively leaving the outermost part of the blades of the distal end portion uncoated. The distribution of the nanoparticles is thus non uniform along the surface of the file leaving only a part of the file coated. In the present invention, the distal end of the device being subjected to the highest torque is either uncoated at all, or has a coated core and uncoated blades. | 07-11-2013 |
20130171108 | USE OF ANTI THIRD PARTY CENTRAL MEMORY T CELLS FOR ANTI-LEUKEMIA/LYMPHOMA TREATMENT - A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject. | 07-04-2013 |
20130156794 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS - A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes. | 06-20-2013 |
20130148413 | SOLID, MULTI-STATE MOLECULAR RANDOM ACCESS MEMORY - A solid-state, multi-valued, molecular random access memory (RAM) device, comprising an electrically, optically and/or magnetically addressable unit, a memory reader, and a memory writer. The addressable unit comprises a conductive substrate; one or more layers of electrochromic, magnetic, redox-active, and/or photochromic materials deposited on the conductive substrate; and a conductive top layer deposited on top the one or more layers. The memory writer applies a plurality of predetermined values of potential biases or optical signals or magnetic fields to the unit, wherein each predetermined value applied results in a uniquely distinguishable optical, magnetic and/or electrical state of the unit, thus corresponding to a unique logical value. The memory reader reads the optical, magnetic and/or electrical state of the unit. | 06-13-2013 |
20130142863 | PHOSPHATIDYLCHOLINE LIPID LIPOSOMES AS BOUNDRY LUBRICANTS IN AQUEOUS MEDIA - The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction. | 06-06-2013 |
20130130311 | METHODS AND SYSTEMS FOR ASSESSING CLONALITY OF CELL CULTURES - Methods of determining clonality of a cell culture are provided. Also provided are systems employing the above methods in high throughput sample screening. | 05-23-2013 |
20130123098 | ZERO VALENT METAL COMPOSITE, MANUFACTURING, SYSTEM AND METHOD USING THEREOF, FOR CATALYTICALLY TREATING CONTAMINATED WATER - Zero valent metal composite, manufacturing thereof, using thereof, and system including thereof, for (in-situ or ex-situ) catalytically treating contaminated water, such as sub-surface water, surface water, above-surface water, water vapor, or/and gaseous water. Composite includes powdered diatomite matrix incorporated with nanometer (1-1000 nm) sized particles of a zero valent (transition) metal (iron, cobalt, nickel, copper, zinc, palladium, platinum, or/and gold) and at least one electron transfer mediator (catalyst) from porphyrinogenic organometallic complexes (e.g., metalloporphyrins (chlorophylls, hemes, cytochromes) or metallocorrins (e.g., vitamin B | 05-16-2013 |
20130116175 | REVERSIBLE PEGYLATED DRUGS - Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety. | 05-09-2013 |
20130111631 | TRANSGENIC PLANTS HAVING ALTERED DAHP SYNTHASE ACTIVITY | 05-02-2013 |
20130098440 | PHOTOVOLTAIC CELL AND METHOD OF ITS MANUFACTURE - A method is presented for use in manufacture of a semiconductor device, such as a photovoltaic cell. The method comprises: providing a structure comprising a ZnO layer; applying a surface treatment to said structure for a certain time period to form a layer of ZnS on said ZnO layer; and depositing an active structure on said ZnS layer. The active structure may be a light absorbing structure, including a light absorbing semiconductor or a molecular light absorbing dye. The provision of the ZnS buffer layer between the ZnO layer and the active structure improves the device performance. | 04-25-2013 |
20130084619 | MODIFIED CELLULASES WITH ENHANCED THERMOSTABILITY - The present invention relates to modified family-8 cellulases that exhibit enhanced thermostability compared to the corresponding wild-type enzyme, polynucleotides encoding the modified cellulases, compositions comprising same and uses thereof. The variant family-8 cellulases are advantageous for the bioconversion process of cellulosic substrates. | 04-04-2013 |
20130079390 | NUCLEIC ACID MOLECULES, POLYPEPTIDES, ANTIBODIES AND COMPOSITIONS FOR TREATING AND DETECTING INFLUENZA VIRUS INFECTION - Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection. | 03-28-2013 |
20130039922 | ANTIBODIES THAT INHIBIT METALLOPROTEINS - The present application relates to antibodies which recognize [2 (2-aminoethylcarbomoyl)-ethoxymethyl]-tris-[2-N-(3-imidazol-1-yl-propyl))-ethoxymethyl]methane, a hapten molecule which closely mimics the local structure and conformation of the reactive zinc site in matrix metalloproteinases. An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed. | 02-14-2013 |
20130035254 | DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - The present invention relates to methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject. Particularly, the present invention relates to a specific antibody profile useful in diagnosing SLE in a subject. | 02-07-2013 |
20130034565 | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES - A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed. | 02-07-2013 |
20130030158 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12. | 01-31-2013 |
20130010295 | SYSTEM AND METHOD FOR POLARIZATION MEASUREMENT - A system and method are presented for use in measuring polarization of an optical beam. The system is configured and operable for determining polarization profile along a cross section of the input optical beam, and comprises an optical system and a pixel matrix. The optical system comprises a polarization beam splitting assembly configured and operable for splitting said input optical beam into a predetermined number of beam components with a predetermined polarization relation between them, the polarization beam splitting assembly comprising a first polarization beam splitter in an optical path of the input optical beam splitting said input optical beam into a first plurality of beam components with a certain polarization relation between them and a birefringent element in an optical path of said first plurality of the beam components for splitting each of them into a pair of beams having ordinary and extraordinary polarizations, thereby producing said predetermined number of output beam components. The pixel matrix is located in substantially non intersecting optical paths of said output beam components and generates a corresponding number of output data pieces indicative of intensity distribution within said output beam components, respectively, data contained in said data pieces being indicative of the polarization profile along the cross section of the input optical beam. | 01-10-2013 |
20130005651 | DEATH ASSOCIATED PROTEIN 1 VARIANTS AND USE THEREOF FOR MODULATING AUTOPHAGY - The present invention relates to methods for the modulation of autophagy by altering the phosphorylation of Death Associated Protein (DAP1). The present invention further relates to methods of treating autophagy associated diseases comprising the suppression of autophagy by dephosphorylating DAP1. The invention further provides human DAP1 mutated at positions 3 and 51 with phospho-silencing residues and uses thereof in treating autophagy associated diseases. | 01-03-2013 |
20120329091 | RECOMBINANT PROTEIN PRODUCTION IN HETEROLOGOUS SYSTEMS - Isolated polynucleotides are disclosed which increase the efficiency of gene expression in a heterologous cell. The polynucleotide sequences which encode polypeptides are adapted such that the average rate of translation of the first at least about 30 amino acids is slower by at least two fold than the average rate of translation of the remaining amino acids of the polypeptide. | 12-27-2012 |
20120321668 | PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE - The present invention relates to peptides, derivatives and analogs comprising an amino acid sequence derived from the transmembrane domain of HIV gp41 protein, pharmaceutical compositions comprising same, and uses thereof for therapy of inflammatory diseases and disorders, such as T-cell and/or monocyte mediated diseases. | 12-20-2012 |
20120319498 | EFFICIENT ROBUST WIRELESS ENERGY TRANSFER - A method or apparatus for transferring energy between a source coil and a drain coil, comprises setting an initial resonant frequency of the source coil as a first condition; setting the source coil and said drain coil in positions relative to each other to define an initial coupling coefficient therebetween, so that the initial coupling coefficient comprises a second condition; and adiabatically changing one or both of the conditions while pumping energy into the source coil. The source coil energy is transferred to the drain coil over the course of the adiabatic change. | 12-20-2012 |
20120316106 | SYNERGISTIC ANTIBIOTIC COMBINATIONS AND DERIVATIVES - Improved antibiotic analogs, and synergistic combinations of antibiotics designed based on structural crystallographic analysis, are provided as well as pharmaceutical compositions that include these improved analogs and synergistic combinations, along with methods for their production and use. The synergistic combinations target neighboring sites in the ribosome demonstrating the importance of the corresponding ribosomal sites for development of clinically-relevant synergistic antibiotics. | 12-13-2012 |
20120301947 | ENZYMATIC SYSTEMS FOR CARBON FIXATION AND METHODS OF GENERATING SAME - A system for carbon fixation is provided. The system comprises enzymes which catalyze reactions of a carbon fixation pathway, wherein at least one of the reactions of the carbon fixation pathway is a carboxylation reaction, wherein products of the reactions of the carbon fixation pathway comprise oxaloacetate and malonyl-CoA, wherein an enzyme which performs the carboxylation reaction is selected from the group consisting of phophoenolpyruvate (PEP) carboxlase, pyruvate carboxylase and acetyl-CoA carboxylase and wherein an export product of the carbon fixation pathway is glyoxylate. Additional carbon fixation pathways are also provided and methods of generating same. | 11-29-2012 |
20120301930 | BIO-ENGINEERED MULTI-ENZYME COMPLEXES COMPRISING XYLANASES AND USES THEREOF - The present invention relates to bio-engineered multi-enzyme complexes having synergistic enzyme activity comprising xylanases and optionally further comprising additional carbohydrate active enzymes. Such complexes are advantageous for degrading recalcitrant cellulosic biomass. | 11-29-2012 |
20120294801 | CONJUGATES OF RGD PEPTIDES AND PORPHYRIN OR (BACTERIO)CHLOROPHYLL PHOTOSYNTHESIZERS AND THEIR USES - Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques. | 11-22-2012 |
20120282648 | METHOD AND SYSTEM FOR DETECTING AND GRADING PROSTATE CANCER - A method of analyzing a plurality of biopsy cores extracted from a plurality of respective biopsy locations in a prostate is disclosed. The method comprises: measuring a level of a chemical element in each of the biopsy cores, and generating a chemical element map of at least a portion of the prostate based on the levels and the respective biopsy locations. In some embodiments, the method determines at least one additional biopsy location for a future biopsy in the prostate. | 11-08-2012 |
20120281923 | DEVICE, SYSTEM, AND METHOD OF IMAGE PROCESSING UTILIZING NON-UNIFORM IMAGE PATCH RECURRENCE - A method of image processing is disclosed, the method implementable on an electronic device, the method comprising: calculating for an image patch within an image at least one patch-dependent content information; based on said at least one patch-dependent content information, determining a patch-dependent search region; searching said patch-dependent search region for one or more image patches that are similar to said image patch; and processing said image patch based on said similar image patches found in said patch-dependent search region. | 11-08-2012 |
20120272958 | DEVICE AND METHOD FOR CONTROLLING RESPIRATION DURING SLEEP - A device for controlling respiration during sleep, the device comprising:
| 11-01-2012 |
20120263719 | COMPOSITIONS AND METHODS FOR TREATING ASPERGILLOSIS - The present invention provides monoclonal antibodies specific for members of the | 10-18-2012 |
20120253042 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES - A process for preparing amides by reacting a primary amine and a primary alcohol in the presence of a Ruthenium complex to generate the amide and molecular hydrogen. Primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. Also disclosed are processes for hydrogenation of amides to alcohols and amines; hydrogenation of organic carbonates to alcohols; hydrogenation of carbamates or urea derivatives to alcohols and amines; amidation of esters; acylation of alcohols using esters; coupling of alcohols with water and a base to form carboxylic acids; dehydrogenation of beta-amino alcohols to form pyrazines and cyclic dipeptides; and dehydrogenation of secondary alcohols to ketones. These reactions are catalyzed by a Ruthenium complex which is based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3. | 10-04-2012 |
20120218262 | ANIMATION OF PHOTO-IMAGES VIA FITTING OF COMBINED MODELS - An image animation method implementable in software includes: fitting a fitting model to at least an object in the image, and animating the object in accordance with a corresponding animation model, where the fitting model is at least as rigid as the animation model, and the animation model is no more rigid than the fitting model. | 08-30-2012 |
20120213834 | ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE - An isolated polypeptide comprising the amino acid sequence of serum paraoxonase (PON1) having catalytic efficiency of k | 08-23-2012 |
20120197033 | OXIDATION OF PRIMARY ALIPHATIC ALCOHOLS WITH A NOBLE METAL POLYOXOMETALATE COMPLEX - A process of oxidizing primary alcohols to their corresponding aldehydes is disclosed. The process is effected in the presence of noble metal polyoxometalate complexes. A novel process for preparing noble metal polyoxometalate complexes, and novel noble metal polyoxometalate complexes are also disclosed. | 08-02-2012 |
20120189574 | METHODS FOR HEMATOPOIETIC PRECURSOR MOBILIZATION - Methods of modulating mobilization of cells from the bone marrow are provided. In a specific embodiment there is provided a method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a subject in need thereof, the method comprising: (a) administering to the subject an agent which downregulates an activity or expression of a coagulation factor or an effector thereof; and (b) harvesting the hematopoietic precursors from the peripheral blood. | 07-26-2012 |
20120186251 | SOLAR POWER PLANT - The present invention provides a novel solar steam generator comprising solar steam boiler compartment carrying water surrounding an internal superheater compartment. The boiler compartment is exposed to a first concentrated solar radiation. The boiler compartment is configured and operable to heat water to saturated temperatures and generate saturated steam. The boiler compartment operates as an integrated cavity enclosing the superheater compartment, reducing the thermal losses of the superheater compartment to the outside environment and absorbs most of the thermal losses of the superheater compartment. The internal superheater compartment is exposed to a second concentrated solar radiation and is configured and operable to superheat the saturated steam generated in the boiler compartment. The boiler compartment and the superheater compartment are thus arranged one with respect to the other such that the boiler compartment surrounds the internal superheater compartment. | 07-26-2012 |
20120144504 | CASPASE-8 AND SKIN DISEASE - The invention relates to the treatment or prevention of an inflammatory skin disease, disorder or condition, by modulating a protein that is normally regulated by caspase-8 in the skin or by increasing caspase-8 activity or level in the skin. Another aspect of the invention relates to methods for diagnosing an inflammatory skin disease, disorder or condition or a predisposition to develop said disease disorder or condition in an individual. Further aspects of the invention relate to methods for identifying target proteins involved in the course or pathology of an inflammatory skin disease, disorder or condition and to methods of screening a candidate compound for treating said disease, disorder or condition. In particular, the invention relates to inflammatory skin diseases such as atopic dermatitis and psoriasis. | 06-07-2012 |
20120134977 | PRODRUGS CONTAINING ALBUMIN BINDING PROBE - The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof. | 05-31-2012 |
20120101365 | ASSESSMENT OF BLOOD-BRAIN BARRIER DISRUPTION - A method of analyzing a blood-brain bather of a subject is disclosed. A detectable dose of an MRI contrast agent is administered to the subject, and a plurality of magnetic resonance images of the subject's brain are acquired over a predetermined time-period. Two or more of the magnetic resonance images are compared thereamongst so as to determine variations in concentration of the contrast agent in the brain, and blood-brain barrier function is assessed based on the variations. | 04-26-2012 |
20120093842 | CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH - Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods. | 04-19-2012 |
20120086850 | SUPER RESOLUTION FROM A SINGLE SIGNAL - A method implementable on a computing device includes exploiting data redundancy to combine high frequency information from at least two different scales of an input signal to generate a super resolution version of said input signal. An alternative method includes exploiting recurrence of data from an input signal in at least two different scales of at least one reference signal to extract and to combine high frequency information from a plurality of scales of said at least one reference signal to generate a super resolution version of said input signal. An alternative method includes generating a super resolution version of a single input video sequence in at least the temporal dimension by exploiting data recurrence within the input video sequence or with respect to an external database of example video sequences. A signal may be an image, a video sequence, an audio signal, etc. | 04-12-2012 |
20120083477 | PROTEASOME INHIBITORS AND USES THEREOF - A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors. | 04-05-2012 |
20120070449 | METHODS OF TREATING INFLAMMATION - A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation. | 03-22-2012 |
20120060418 | CATALYTIC GASIFICATION OF ORGANIC MATTER IN SUPERCRITICAL WATER - A catalyst system including at least one metal and an oxide support, said oxide support including at least one of Al | 03-15-2012 |
20120058945 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group. | 03-08-2012 |
20120045411 | SHORT BETA-DEFENSIN-DERIVED PEPTIDES - The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. | 02-23-2012 |
20120040993 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition. The present invention encompasses compounds of the formulas I to VI. | 02-16-2012 |
20120028887 | LIPOPEPTIDE INHIBITORS OF HIV-1 - The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety possesses anti-fusogenic activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV. | 02-02-2012 |
20120010836 | ELECTROMAGNETIC RADIATION MAPPING SYSTEM - Apparatus for radiation mapping of a region comprises a spectrum analyzer for analyzing a local radiation field according to wavelength, and a positioning unit for obtaining a position reading to correlate with said local radiation field, thereby to provide said radiation mapping. The results may be provided as layers to a map, and different layers may be provided for different frequencies and different times of the day. | 01-12-2012 |
20120003236 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 01-05-2012 |
20110314813 | SOLAR RECEIVER SYSTEM - A solar receiver is provided. The solar receiver may include a receiver housing with front and rear ends. The solar receiver may also include a window configured to allow radiation to pass therethrough. The window may be mounted at the front end and project within the housing. The solar receiver may also include a receiver chamber defined between the housing and the window. The receiver chamber may include a working fluid inlet for ingress of working fluid to be heated therewithin, and a working fluid outlet for egress therethrough of the heated working fluid. The solar receiver may also include a solar radiation absorber configured for absorbing the radiation and heating the working fluid thereby. The absorber may be located within the receiver chamber and may surround at least a portion of the window. The solar radiation absorber may be formed with projections. | 12-29-2011 |
20110306503 | TEMPLATE-DEPENDENT NUCLEIC ACID POLYMERIZATION USING OLIGONUCLEOTIDE TRIPHOSPHATES BUILDING BLOCKS - A novel use of a template-dependent polymerase. The novel use is effected by employing the template-dependent polymerase for incorporating at least one oligonucleotide triphosphate onto a nascent oligonucleotide-3′-OH in a template-dependent manner. | 12-15-2011 |
20110301065 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 12-08-2011 |
20110294134 | METHODS AND KITS FOR DETERMINING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER - Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed. | 12-01-2011 |
20110293593 | SIVA 2 STABILIZATION - The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions. | 12-01-2011 |
20110286932 | OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE - The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively. | 11-24-2011 |
20110283700 | SOLAR COMBINED CYCLE POWER SYSTEMS - A combined cycle power system is provided including at least one solar power plant including a concentrating dish configured to concentrate solar radiation; a solar receiver disposed and configured to utilize concentrated solar radiation for heating a first working fluid, and a first turbine configured for generating electricity by expansion therein of the heated first working fluid, and at least one recovery power plant including a heat recovery unit configured for utilizing exhaust heat of the first turbine to heat a second working fluid, and a second turbine configured for generating electricity by expansion therein of the heated second working fluid. | 11-24-2011 |
20110274647 | IL6R/IL6 Chimera for Therapy of Chemotherapy-Induced Peripheral Neuropathy - The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy. | 11-10-2011 |
20110268712 | Stem Cells Suitable for Transplantation, Their Preparation and Pharmaceutical Compositions Comprising Them - The present invention relates to stem cells suitable for transplantation and to methods for their preparation. | 11-03-2011 |
20110265224 | CONTROL OF SO2 METABOLISM IN PLANTS AND ITS APPLICATIONS - SO-transgenic plants overexpressing or lacking SO activity, having modified tolerance or susceptibility to toxicity of sulfite-producing substances, methods for their production and the use thereof for bioremediation of pollutants, as sentinel plants, for enhancing post-harvest quality of plants, plant tissues and plant products and for therapeutic applications. | 10-27-2011 |
20110239312 | METHODS OF DIAGNOSING AND TREATING MOTOR NEURON DISEASES - Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND). | 09-29-2011 |
20110236975 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK - The present invention provides for isolated polypeptides capable of binding ErbB-4. | 09-29-2011 |
20110224407 | Type I Interferon Antagonists - Disclosed in certain embodiments is a method of preparing a Type 1 interferon antagonist comprising modifying a Type 1 interferon at the site of interaction with the interferon receptor subunit IFNAR-1 such that the binding affinity of the interferon to the IFNAR-1 subunit is reduced as compared to the native interferon, and corresponding compositions and methods of treatment thereof. | 09-15-2011 |
20110212071 | ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT - An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided. | 09-01-2011 |
20110206706 | VACCINE AND METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii). | 08-25-2011 |
20110195083 | CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE - Isolated cyclic polypeptides useful as vaccinations for the treatment/prevention of HIV are disclosed. An exemplary peptide comprises at least 18 consecutive amino acids of a V3 domain of gp120, starting at position 303 and ending at position 322, the positioning being according to a numbering of the V3 domain of gp120 in a HXB2 strain, wherein amino acids at position 303 and 322 are bonded. Vaccines comprising same and methods of treating AIDS using same are also disclosed. | 08-11-2011 |
20110189202 | COMPOSITIONS COMPRISING SOLUBLE CD84 OR ANTI-CD84 ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING B-CLL - A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL. | 08-04-2011 |
20110183437 | METHODS OF IDENTIFYING COMBINATIONS OF ANTIBODIES WITH AN IMPROVED ANTI-TUMOR ACTIVITY AND COMPOSITIONS AND METHODS USING THE ANTIBODIES - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity. | 07-28-2011 |
20110177065 | METHODS OF TREATING/PREVENTING INFLAMMATION USING COMBINATION OF IL-1 ANTAGONIST AND IL-18 BINDING PROTEIN - The invention relates to the combined use of an IL-1 antagonist/inhibitor and IL-18 binding protein in inflammatory diseases. | 07-21-2011 |
20110171197 | PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND COMPOSITIONS AND METHODS UTILIZING SAME - Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes. | 07-14-2011 |
20110165116 | PHARMACEUTICAL COMPOSITIONS COMPRISING CCL2 AND USE OF SAME FOR THE TREATMENT OF INFLAMMATION - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 07-07-2011 |
20110129937 | SEMICONDUCTOR DETECTOR FOR PEROXIDE-BASED EXPLOSIVES - A device for the detection of a peroxide-based explosive, in particular, triacetone triperoxide (TATP), which is based on a molecular controlled semiconductor resistor (MOCSER) and composed of at least one insulating or semi-insulating layer, at least one conducting semiconductor layer, two conducting pads and a layer of multifunctional organic molecules capable of adsorbing molecules of said peroxide-based explosive. Further is provided an array of semiconductor devices for the selective detection of a peroxide-based explosive, as well as a method for the selective detection of vapors of a peroxide-based explosive in a gaseous mixture using said array. The multifunctional organic molecules are from the group of cyclodextrins, thiols or alkylphosphonates with RPO(OH) 2 wherein R is an aliphatic hydrocarbyl with C6-C22. | 06-02-2011 |
20110123480 | CHIMERIC PROTEINS AND USES THEREOF - The present invention provides a chimeric protein capable of killing or modifying a cell expressing abnormally high levels of a ligand of a receptor of the TNF/NGF family, comprising the amino acid sequence of at least one polypeptide consisting of an extracellular portion of said receptor connected to an effector molecule. In addition the invention provides pharmaceutical compositions comprising said chimeric protein and use thereof. | 05-26-2011 |
20110117029 | WATER-SOLUBLE ANIONIC BACTERIOCHLOROPHYLL DERIVATIVES AND THEIR USES - The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis. | 05-19-2011 |
20110104167 | Compositions and Methods for Diagnosing and Treating Insulin Resistance - A method of treating insulin resistance in a subject is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of down-regulating phosphorylation of an IRS protein at at least one serine residue corresponding to amino acid 341, 412 and/or 413 of human IRS-1, thereby treating the insulin resistance in the subject. Also provided are methods and kits for diagnosing insulin resistance. | 05-05-2011 |
20110059536 | HEXAVALENT CHROMIUM DETECTOR - The present invention relates to a molecular-based system for the optical detection, quantification and detoxification of hexavalent chromium (Cr | 03-10-2011 |
20110044999 | IL-32 MODULATORS - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. | 02-24-2011 |
20110040170 | ENDOSCOPIC IMAGING PHOTODYNAMIC THERAPY SYSTEM AND METHODS OF USE - The invention provides an endoscopic imaging photodynamic therapy system (EIPS) for focused tissue ablation by illumination of a photosensitizer drug in a target tissue, said system comprising an endoscopic assembly, a real-time imaging component for locating the target tissue and monitoring the ablation intervention, a therapeutic light system and, optionally, a drug delivery module, wherein said imaging component comprises a flexible transducer with an operative channel for insertion of a flexible light guide of the therapeutic light system and, optionally, a flexible drug delivery catheter of the drug delivery module. This EIPS may be used in various medical applications where tissue ablation is required and photodynamic therapy may be applied, in particular, in the treatment of extrauterine pregnancy (EUP). | 02-17-2011 |
20110035817 | SIVA 3, ITS PREPARATION AND USE - The present invention relates to a splice variant of SIVA, SIVA3, and to its use. | 02-10-2011 |
20110033488 | AGENTS AND METHODS FOR TREATMENT OF ANXIETY DISORDERS - Peptides derived from CNS-specific antigens, altered peptide ligands (APL) analogues of said peptides, T cells activated by such peptides, poly-YE, and any combination of said agents are useful for prevention, treatment and/or alleviation of anxiety disorders, particularly post-traumatic stress disorder, and for restoring BDNF levels in the brain of an individual after reduction of BDNF expression induced by stress. | 02-10-2011 |
20110009745 | Ultrasonically determining flow parameters of a fluid flowing through a passage, by using far-field analysis - Ultrasonically determining flow parameters of a fluid ( | 01-13-2011 |
20110003379 | CHIMERIC AUTOPROCESSING POLYPEPTIDES AND USES THEREOF - A chimeric polypeptide comprising an autoprocessing segment having an amino acid sequence being capable of auto-cleavage, a polynucleotide encoding such a polypeptide, and uses of such a polypeptide and such a polynucleotide are provided. a polynucleotide are provided. | 01-06-2011 |
20100322928 | METHODS OF DIAGNOSING, MONITORING TREATMENT AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and/or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE. | 12-23-2010 |
20100312072 | METHOD AND SYSTEM FOR DETECTING AND GRADING PROSTATE CANCER - A method of estimating a grade of a prostate cancer from zinc data associated with the prostate, the zinc data being arranged gridwise in a plurality of picture-elements representing a zinc map of the prostate. The method comprises, clustering the zinc map according to zinc levels associated with the picture-elements, and estimating a cancer grade of at least one tissue region, based, at least in part, on zinc levels associated with a cluster of picture-elements representing the tissue region. | 12-09-2010 |
20100291127 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 11-18-2010 |
20100279359 | TEMPLATE-DEPENDENT NUCLEIC ACID POLYMERIZATION USING OLIGONUCLEOTIDE TRIPHOSPHATES BUILDING BLOCKS - A novel use of a template-dependent polymerase. The novel use is effected by employing the template-dependent polymerase for incorporating at least one oligonucleotide triphosphate onto a nascent oligonucleotide-3′-OH in a template-dependent manner. | 11-04-2010 |
20100279302 | METHODS OF PREDICTING PAIRABILITY AND SECONDARY STRUCTURES OF RNA MOLECULES - Provided are methods of predicting a pairability of nucleotides of a plurality of RNA polynucleotides by (a) simultaneously determining a paired state or an unpaired state of nucleotides of the plurality of RNA polynucleotides; and (b) corresponding the paired state or the unpaired state of the nucleotides to a database of nucleic acid sequences, the database comprises nucleic acid sequences representing the plurality of RNA polynucleotides, thereby determining the pairability of nucleotides of the plurality of RNA polynucleotides. Also provided are methods of determining a secondary structure of a plurality of RNA molecules; methods of determining if a molecule is capable of modulating a secondary structure of at least one RNA polynucleotide of a plurality of RNA polynucleotides; and methods of screening for a marker associated with a pathology. | 11-04-2010 |
20100278853 | CONSTRAINED HIV V3 LOOP PEPTIDES AS NOVEL IMMUNOGENS AND RECEPTOR ANTAGONISTS - The present invention provides constrained peptides and other organic molecules, that mimic the three dimensional characteristics of the HIV-1 V3 loop peptide when bound by a highly potent human neutralizing monoclonal antibody specific for a V3 conformational epitope, which structure is determined by NMR. Methods for screening for, and designing such molecules are disclosed. These molecules are useful as immunogens for inducing broadly-neutralizing antibodies against HIV-1 as well as antagonists for inhibiting the binding of HIV-1 to the relevant co-receptors, and may therefore be used in method of preventing or treating HIV-1 infection and disease. | 11-04-2010 |
20100270228 | Methods, Compositions And Devices For Maintaining Chemical Balance Of Chlorinated Water - A composition-of-matter for use in water treatment, composed of a water-insoluble matrix and one or more amidohydrolase, such as cyanuric acid amidohydrolase, incorporated in or on the matrix, is disclosed. Also disclosed are devices containing same and methods utilizing same for water treatment. The water treatment is effected by an enzymatically-catalyzed reduction of the concentration of an amide-containing compound, such as cyanuric acid, found in chlorinated water of swimming polls, spas and other similar structures. | 10-28-2010 |
20100259546 | MODELIZATION OF OBJECTS IN IMAGES - A system includes an aligner to align an initial position of an at least partially kinematically, parameterized model with an object in an image, and a modelizer to adjust parameters of the model to match the model to contours of the object, given the initial alignment. An animation system includes a modelizer to hierarchically match a hierarchically rigid model to an object in an image, and a cutter to cut said object from said image and to associate it with said model. A method for animation includes hierarchically matching a hierarchically rigid model to an object in an image, and cutting said object from said image to associate it with said model. | 10-14-2010 |
20100221270 | THERAPEUTIC TRANSPLANTATION USING DEVELOPING, HUMAN OR PORCINE, RENAL OR HEPATIC, GRAFTS - A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage. | 09-02-2010 |
20100204091 | SIVA Ubiquitination and/or Degradation-Related Activity and Modulators Thereof - The present invention relates to the ubiquitination and/or degradation-related activity of a SIVA polypeptide and to agents capable of modulating said activity. | 08-12-2010 |
20100193407 | Device and Method For Particle Manipulation in Fluid - A device for manipulating particles present in a fluid medium is disclosed. The device comprises a planar substrate, formed with at least one primary microchannel to allow passage of the fluid medium therethrough. The primary microchannel(s) has walls and a base and being in fluid communication with a plurality of secondary microchannels via at least one branching point. The device further comprises one or more ultrasound transmission pairs, positioned at opposite sides of the walls to generate ultrasound waves propagating through the fluid medium, substantially parallel to the planar substrate, such as to form a standing wave within the primary microchannel. | 08-05-2010 |
20100189750 | METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES - A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject. | 07-29-2010 |
20100135974 | REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE - A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease. | 06-03-2010 |
20100135953 | Method of treatment of age-related macular degeneration - The invention provides methods and compositions for treatment of age-related macular degeneration, which comprises causing T cells that produce IL-4 to accumulate in the eye by administration of an agent such as Copolymer-1, IL-4, cells activated with IL-4, IL-13 or up to 20 ng/ml IFN-g, or a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of the eye or a peptide derived therefrom, and any combination of such agents. | 06-03-2010 |
20100099627 | NUCLEAR TARGETING SEQUENCES - Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed. | 04-22-2010 |
20100099118 | METHODS OF DETERMINING TOTAL PON1 LEVEL - A method of determining an amount of total PON1 in a sample of a subject is disclosed. The method comprises:
| 04-22-2010 |
20100087363 | GLYCAN MODIFIED SOLUBLE RECEPTORS AND BINDING PROTEIN AND THEIR USE - An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc. | 04-08-2010 |
20100069478 | ISOFLAVONE DERIVATIVES AND USES THEREOF - Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and the functional group B is preferably an amino protecting group. These isoflavone derivatives are useful for treating or preventing diseases or disorders associated with estrogen receptor functioning. | 03-18-2010 |
20100048863 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK - A method of diagnosing a disease or syndrome associated with disregulation of Neuregulin-4 (NRG-4), Aa novel ErbB-4 ligand, referred to herein as Neuregulin-4 (NRG-4)in a subject is disclosed. The method comprising: (a) obtaining a sample from a subject; (b) incubating the sample with at least one oligonucleotide or oligonucleotide analog of at least bases, said oligonucleotide or oligonucleotide analog capable of hybridizing to a portion of a polynucleotide strand encoding NRG-4 to thereby diagnosing the disease, condition or syndrome associated with disregulation of NRG-4. | 02-25-2010 |
20100041043 | METHOD FOR THE DIAGNOSIS AND FOLLOW-UP OF SCHIZOPHRENIA AND OTHER MENTAL AND NEUROLOGICAL DISORDERS - A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D | 02-18-2010 |
20100029758 | DERIVATIVES OF ISOFLAVONES - The present invention discloses novel isoflavone conjugates and their use for affinity targeting of drugs, imaging and detection agents to cells having estrogen receptors, particularly estrogen receptors subtype β. | 02-04-2010 |
20100021489 | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection - Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection. | 01-28-2010 |
20100021433 | Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 01-28-2010 |
20100003751 | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns - A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. | 01-07-2010 |
20090324607 | Therapeutic Transplantation Using Developing, Human or Porcine, Renal or Hepatic, Grafts - A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage. | 12-31-2009 |
20090318346 | BIVALENT ErbB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE - A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding molecules act as traps to bind and sequester ligands, thus making them unavailable for binding to cellular ErbB receptors. | 12-24-2009 |
20090305954 | HISTIDINE-CONTAINING DIASTEREOMERIC PEPTIDES AND USES THEREOF - Diastereomeric peptides with a net positive charge greater than +1, and cyclic derivatives thereof, are provided, having at least 13 amino acid residues, comprising histidine and one or more hydrophobic amino acid residues, optionally esterified or amidated at the C-terminus and/or acylated at the N-terminus. The peptides may contain other amino acid residues including non-natural amino acids. The peptides are particularly useful in the treatment of cancer. | 12-10-2009 |
20090297515 | Use of Caspase-8 Inhibitors for Modulating Hematopoiesis - A method of inhibiting hematopoiesis in a subject is provided. The method is effected by downregulating an expression or activity of caspase-8 in the subject thereby inhibiting hematopoiesis therein. | 12-03-2009 |
20090292482 | Methods and Systems for Generating Cell Lineage Tree of Multiple Cell Samples - A method of generating a cell lineage tree of a plurality of cells of an individual is provided. The method comprising: (a) determining at least one genotypic marker for each cell of the plurality of cells; and (b) computationally clustering data representing the at least one genotypic marker to thereby generate the cell lineage tree of the plurality of cells of the individual. | 11-26-2009 |
20090291888 | MODULATORS OF TNF RECEPTOR ASSOCIATED FACTOR (TRAF), THEIR PREPARATION AND USE - A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins. | 11-26-2009 |
20090269331 | CASPASE-8 AND INFLAMMATION, INFECTION AND WOUND HEALING - The present invention relates to the regulatory role of caspase-8 in infection by intracellular pathogen, inflammation and wound healing | 10-29-2009 |
20090263354 | Compositions and siRNAs for inhibiting C/EBPbeta - The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy. | 10-22-2009 |
20090258790 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 10-15-2009 |
20090239799 | Pharmaceutical Compositions Comprising Ccl2 and Use of Same For The Treatment of Inflammation - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 09-24-2009 |
20090232774 | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject | 09-17-2009 |
20090214470 | EYE-DROP VACCINE CONTAINING COPOLYMER 1 FOR THERAPEUTIC IMMUNIZATION - The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity. | 08-27-2009 |
20090208510 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 08-20-2009 |
20090208506 | Antibodies against flagellin and uses thereof - The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, | 08-20-2009 |
20090191162 | Catecholamine Receptor Modulation - The invention relates to receptors of catecholamines and their role in stem cell development and function. | 07-30-2009 |
20090155288 | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity. | 06-18-2009 |
20090137999 | METHOD OF AND SYSTEM FOR SELECTIVE CELL DESTRUCTION - Method and apparatus for the ionization of living cells where an optical device ( | 05-28-2009 |
20090136462 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 05-28-2009 |
20090127208 | ZERO VALENT METAL COMPOSITE, MANUFACTURING, SYSTEM AND METHOD USING THEREOF, FOR CATALYTICALLY TREATING CONTAMINATED WATER - Zero valent metal composite, manufacturing thereof, using thereof, and system including thereof, for (in-situ or ex-situ) catalytically treating contaminated water, such as sub-surface water, surface water, above-surface water, water vapor, or/and gaseous water. Composite includes powdered diatomite matrix incorporated with nanometer (1-1000 nm) sized particles of a zero valent (transition) metal (iron, cobalt, nickel, copper, zinc, palladium, platinum, or/and gold) and at least one electron transfer mediator (catalyst) from porphyrinogenic organometallic complexes (e.g., metalloporphyrins (chlorophylls, hemes, cytochromes) or metallocorrins (e.g., vitamin B | 05-21-2009 |
20090124564 | Compositions and methods for regulating apoptosis - Methods and pharmaceutical compositions for regulating apoptosis and treating pathologies associated with disregulated apoptosis are provided. Specifically the present invention provides agents capable of modulating the expression of an MCD-containing protein (e.g., Mtch2) capable of tBID binding activity and/or the tBID binding activity of the MCD-containing protein. | 05-14-2009 |
20090124557 | Compositions and methods for treating cancer - A composition which comprises a chimeric polypeptide is provided. The chimeric polypeptide having a flagellin amino acid sequence and a mucin 1 amino acid sequence which includes at least a 7 amino acid sequence of the mucin 1 tandem repeat which can be used to elicit an immune response against MUC1—expressing cancerous cells. Also provided is a method of treating cancer such as a cancer of a glandular epithelium in which MUC1 is overexpressed using the composition of the present invention. | 05-14-2009 |